Pyxis Oncology rises on FDA fast track tag for lead asset
Source: SeekingAlpha
2025-02-26 07:55:47 ET
Shares of Pyxis Oncology ( NASDAQ: PYXS ) traded higher in the premarket on Wednesday after the U.S. FDA issued its Fast Track Designation for the company’s lead candidate, PYX-201, targeted at head and neck cancer....
Read the full article on Seeking Alpha
For further details see:
Pyxis Oncology rises on FDA fast track tag for lead asset
Merck & Company Inc.
NASDAQ: MRK
MRK Trading
0.54% G/L:
$114.76 Last:
6,874,509 Volume:
$114.245 Open:
MRK Latest News
March 18, 2026 04:30:00 pm
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
March 17, 2026 06:50:00 am
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
MRK Stock Data
$291,612,827,755
2,457,202,311
0.02%
2165
N/A
Pharmaceuticals
Healthcare
US
Rahway
